Effect of Qinhuang Formula on immune function of patients with diffuse large B-cell lymphoma after R-CHOP chemotherapy

doi:10.3969/j.issn.1673-8640.2022.05.001

Abstract

Abstract: Objective To investigate the effect of Qinhuang Formula on immune function of patients with diffuse large B-cell lymphoma（DLBCL） after R-CHOP chemotherapy. Methods A total of 300 cases of DLBCL undergoing R-CHOP chemotherapy were analyzed retrospectively and were classified into 2 groups. The treatment group（150 cases） were treated with Qinhuang Formula after chemotherapy for 6 months at least,and the control group（150 cases） were not treated with traditional Chinese medicine after chemotherapy. T cell subsets（the absolute values of CD3⁺T,CD4⁺T and CD8⁺T cells,the ratio of CD4/CD8）,IgG,IgA and IgM were observed in the 2 groups before chemotherapy,3 months after chemotherapy,completing chemotherapy,3 months after completing chemotherapy,6 months after completing chemotherapy,1 year after completing chemotherapy and 2 years after completing chemotherapy. Results The absolute values of CD3⁺T,CD4⁺T cells,CD4/CD8 ratio,the levels of IgG,IgA and IgM were decreased after chemotherapy（P<0.05）. During follow-up period,the absolute value of CD4⁺T cells increased significantly half a year after completing chemotherapy（P<0.05）. IgG was higher at 2 years after completing chemotherapy（P<0.05）. The absolute values of CD3⁺T cells and the ratio of CD4/CD8 in treatment group at 1-2 years after completing chemotherapy returned to the levels before chemotherapy,while those of control group was still lower than those before chemotherapy（P<0.05）. Compared with 3 months after chemotherapy,the absolute values of CD3⁺T and CD4⁺ T cells and the ratio of CD4/CD8 at 2 years after completing chemotherapy in treatment group increased significantly than those in control group（P<0.05）. There was no statistical significance in the absolute value of CD8⁺T cells between the 2 groups at each time point after completing chemotherapy（P>0.05）. The levels of IgG,IgA and IgM in the 2 groups after completing chemotherapy were lower than those before chemotherapy（P<0.05）. IgA returned to pre-chemotherapy level at 1 year after completing chemotherapy,and IgG returned to pre-chemotherapy level at 2 years after completing chemotherapy. IgM level at 2 years after completing chemotherapy was still lower than that before chemotherapy（P<0.05）. There was no statistical significance in the increase of IgG,IgA and IgM between the 2 groups（P>0.05）. Conclusions Long-term immunosuppression is appeared after R-CHOP chemotherapy in patients with DLBCL. Qinhuang Formula can promote the immune function reconstruction of DLBCL patients after chemotherapy.

Key words: T cell subset, Immunoglobulin, Diffuse large B-cell lymphoma, Qinhuang Formula

RUAN Ming, LIN Han, WANG Jianbiao, LÜ Lingling, ZHU Wenhua, XU Jiayue, LI Weili, ZHU Weirong. Effect of Qinhuang Formula on immune function of patients with diffuse large B-cell lymphoma after R-CHOP chemotherapy[J]. Laboratory Medicine, 2022, 37(5): 403-408.

Figures/Tables 11

References 10

[1]	CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI URL
[2]	MICHALLET A S, COIFFIER B. Recent developments in the treatment of aggressive non-Hodgkin lymphoma[J]. Blood Rev, 2009, 23(1):11-23. DOI URL
[3]	朱伟嵘, 赵夏, 阮铭, 等. 芩黄合剂对弥漫大B细胞淋巴瘤患者免疫功能的影响[J]. 中成药, 2018, 40(9):1930-1934.
[4]	张之南, 沈悌. 血液病诊断和疗效标准[M]. 3版. 北京: 科学出版社, 2008.
[5]	SWERDLOW S, CAMPO E, HARRIS N L. International agency for research on cancer. WHO classification of tumours of haematopoietic and lymphoid tissue[R]. Geneva: World Health Organization, 2008.
[6]	杨少江, 徐理华, 曾萍, 等. R-CHOP方案对淋巴瘤患者免疫球蛋白及T细胞亚群的影响[J]. 临床血液学杂志, 2014, 27(7):577-580.
[7]	BATTELLA S, COX M C, LA SCALEIA R, et al. Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy[J]. Cancer Immunol Immunother, 2017, 66(10):1295-1306. DOI URL
[8]	KUROKAWA T, HASE M, TOKUMAN N, et al. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab[J]. Hematol Oncol, 2011, 29(1):5-9. DOI URL
[9]	KUSANO Y, YOKOYAMA M, TERUI Y, et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma[J]. Blood Cancer J, 2017, 7(4):e558. DOI URL
[10]	朱伟嵘, 赵夏, 吕玲玲, 等. 芩黄合剂治疗中高危弥漫性大B细胞淋巴瘤患者的随机对照临床研究[J]. 世界中西医结合杂志, 2016, 11(12):1688-1693.

组别	例数	肿瘤分期				体力评分					IPI评分				分子分型
组别	例数	Ⅰ期	Ⅱ期	Ⅲ期	Ⅳ期	0分	1分	2分	3分	4分	0~1分	2分	3分	4分	生发中心型	非生发中心型
中药治疗组	150	63	45	25	17	45	52	40	8	5	28	57	45	20	38	112
对照组	150	65	42	27	16	48	55	38	6	3	30	56	46	18	40	110
χ²值		0.242				1.018					0.194				0.069
P值		0.971				0.907					0.979				0.792

组别	例数	肿瘤分期				体力评分					IPI评分				分子分型
组别	例数	Ⅰ期	Ⅱ期	Ⅲ期	Ⅳ期	0分	1分	2分	3分	4分	0~1分	2分	3分	4分	生发中心型	非生发中心型
中药治疗组	150	63	45	25	17	45	52	40	8	5	28	57	45	20	38	112
对照组	150	65	42	27	16	48	55	38	6	3	30	56	46	18	40	110
χ²值		0.242				1.018					0.194				0.069
P值		0.971				0.907					0.979				0.792

时间点	CD3⁺T细胞/（个/μL）	CD4⁺ T细胞/（个/μL）	CD8⁺ T细胞/（个/μL）
化疗前	983.00（709.00~1 371.00）^#	458.00（321.00~673.00）^#△	404.50（254.00~618.50）
化疗3个月	701.00（510.00~960.00）^*	316.00（230.00~423.75）^*	319.00（201.50~447.00）^*
化疗结束时	790.50（583.00~1 085.00）^*	357.50（258.75~489.25）^*	366.00（252.50~503.50）
化疗结束后3个月	844.00（596.50~1 190.00）^*	384.00（261.50~534.00）^*	375.00（247.00~563.00）
化疗结束后6个月	858.50（682.25~1 084.25）^*#	407.00（296.50~537.50）^#	370.00（279.50~511.00）
化疗结束后1年	918.00（669.50~1 174.00）^#	426.00（305.50~575.50）^#△	383.00（283.00~535.00）
化疗结束后2年	967.00（637.00~1 228.00）^#	435.00（326.00~657.00）^#△	408.00（295.00~562.00）

时间点	CD3⁺T细胞/（个/μL）	CD4⁺ T细胞/（个/μL）	CD8⁺ T细胞/（个/μL）
化疗前	983.00（709.00~1 371.00）^#	458.00（321.00~673.00）^#△	404.50（254.00~618.50）
化疗3个月	701.00（510.00~960.00）^*	316.00（230.00~423.75）^*	319.00（201.50~447.00）^*
化疗结束时	790.50（583.00~1 085.00）^*	357.50（258.75~489.25）^*	366.00（252.50~503.50）
化疗结束后3个月	844.00（596.50~1 190.00）^*	384.00（261.50~534.00）^*	375.00（247.00~563.00）
化疗结束后6个月	858.50（682.25~1 084.25）^*#	407.00（296.50~537.50）^#	370.00（279.50~511.00）
化疗结束后1年	918.00（669.50~1 174.00）^#	426.00（305.50~575.50）^#△	383.00（283.00~535.00）
化疗结束后2年	967.00（637.00~1 228.00）^#	435.00（326.00~657.00）^#△	408.00（295.00~562.00）

组别	例数	化疗前/（个/μL）	化疗3个月/（个/μL）	化疗结束/（个/μL）
中药治疗组	150	916（688~1 368）	687（508~903）^*	717（556~968）^*
对照组	150	1 059（786~1 374）	716（515~1 018）^*	853（679~1 207）^*